5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | NEUTRAL | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.35▼ | 1.37▼ | 1.36▼ | 1.29▲ | 1.24▲ |
MA10 | 1.36▼ | 1.36▼ | 1.36▼ | 1.28▲ | 1.21▲ |
MA20 | 1.37▼ | 1.36▼ | 1.35▼ | 1.25▲ | 1.34▼ |
MA50 | 1.36▼ | 1.34▲ | 1.30▲ | 1.21▲ | 2.10▼ |
MA100 | 1.36▼ | 1.30▲ | 1.29▲ | 1.42▼ | 3.14▼ |
MA200 | 1.35▼ | 1.28▲ | 1.25▲ | 2.07▼ | 7.12▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.003▼ | -0.002▼ | -0.002▼ | 0.005▲ | 0.053▲ |
RSI | 33.717▼ | 47.503▼ | 53.311▲ | 55.595▲ | 42.282▼ |
STOCH | 9.444▼ | 69.808 | 73.825 | 54.496 | 60.428 |
WILL %R | -85.714▼ | -50.000 | -50.000 | -32.432 | -30.411 |
CCI | -104.981▼ | -40.627 | -27.106 | 148.800▲ | 141.406▲ |
Wednesday, May 21, 2025 08:33 AM
Shares of Akoya Biosciences (NASDAQ:AKYA) climbed ~25% on Wednesday after the life sciences company received an unsolicited acquisition proposal that indicated a superior offer compared to its ...
|
Monday, May 12, 2025 02:30 PM
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago. These ...
|
Monday, May 05, 2025 07:00 AM
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/07/25 | 1.30 | 1.38 | 1.30 | 1.32 | 530,730 |
30/06/25 | 1.26 | 1.37 | 1.26 | 1.30 | 440,133 |
27/06/25 | 1.32 | 1.3678 | 1.24 | 1.24 | 4,209,846 |
26/06/25 | 1.30 | 1.34 | 1.28 | 1.33 | 434,566 |
25/06/25 | 1.25 | 1.2998 | 1.205 | 1.28 | 68,877 |
24/06/25 | 1.30 | 1.33 | 1.195 | 1.25 | 488,126 |
23/06/25 | 1.26 | 1.30 | 1.22 | 1.29 | 184,519 |
20/06/25 | 1.31 | 1.31 | 1.25 | 1.26 | 106,893 |
18/06/25 | 1.25 | 1.35 | 1.21 | 1.30 | 310,393 |
17/06/25 | 1.25 | 1.29 | 1.23 | 1.25 | 99,318 |
|
|
||||
|
|
||||
|
|